The proposed UCLA CTSI KL2 grant involves partnerships between UCLA, Charles R. Drew University, Cedars Sinai and LA Biomed, building upon long-standing relationships of jointly training research fellows and junior clinical investigators. Deeply committed to rigorous translational science training, these institutions have been highly successful in developing outstanding scientists through exemplary mentoring, innovative project- based learning, and a wide array of formal didactic opportunities. In this proposal, we propose to build upon the success of our educational and training programs with several innovative additions to the KL2 Program. The KL2 program objectives are to: 1) Enhance career development and research training support for junior investigators in translational science; 2) Provide a flexible, supportive environment to meet the needs of a diverse group of Scholars; 3) Facilitate and improve mentorship through new mentorship training programs; 4) Leverage institutional support and matching funds to expand the KL2 program for additional institutional K Scholars; 5) Foster collaborative research, promote leadership, and encourage entrepreneurship and development of intellectual property among our Scholars and other junior investigators; 6) Improve the recruitment, career development support, mentoring programs, and funding support for women and minority faculty; 7) Provide structured oversight of educational and training needs for all junior investigators. The KL2 Program will select 3 junior faculty (assistant professor or equivalent) per year and provide 3 years of support at 75% effort. We will recruit and train the most promising and diverse junior faculty in a range of disciplines related to translational research. With institutional funds, we will supplement the program with additional institutional career development awards for highly qualified junior faculty. All KL2 Scholars will participate in the KL2 Core Curriculum, which will also be available to other junior faculty with a NIH K or equivalent award. The Core Curriculum includes strong mentorship with a team of senior scientists, training in team science and communication of science, mentorship training in our a ?daisy-chain? mentoring program, seminars in career development, and training in the responsible conduct of research. KL2 Scholars will also be assigned a K to R studio in which a panel of senior faculty will meet regularly with the Scholar to provide grant writing guidance for the Scholar's transition to an R01 award. Additional curriculum will be tailored to each Scholar, depending on their research focus. The KL2 Program will also participate in several activities to increase diversity in the scientific pipeline from high school to faculty level and will actively recruit and support diverse faculty in the KL2 program. Key outcomes for the KL2 Program will be the success rate of KL2 Scholars in obtaining grants (transition to an NIH K01/K08/K23 and to and R or U level grants), number of peer-reviewed publications in high-impact journals, development of intellectual property, and increase in gender and racial/ethnic diversity of faculty.

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Mentored Career Development Award (KL2)
Project #
5KL2TR001882-04
Application #
9739185
Study Section
Special Emphasis Panel (ZTR1)
Program Officer
Chang, Soju
Project Start
2016-07-01
Project End
2021-05-31
Budget Start
2019-06-01
Budget End
2020-05-31
Support Year
4
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Fulcher, Jennifer A; Shoptaw, Steven; Makgoeng, Solomon B et al. (2018) Brief Report: Recent Methamphetamine Use Is Associated With Increased Rectal Mucosal Inflammatory Cytokines, Regardless of HIV-1 Serostatus. J Acquir Immune Defic Syndr 78:119-123
Allyn, P R; O'Malley, S M; Ferguson, J et al. (2018) Attitudes and potential barriers towards hepatitis C treatment in patients with and without HIV coinfection. Int J STD AIDS 29:334-340
Hsu, Jeffrey J; Lu, Jinxiu; Umar, Soban et al. (2018) Effects of teriparatide on morphology of aortic calcification in aged hyperlipidemic mice. Am J Physiol Heart Circ Physiol 314:H1203-H1213
Ware, Deanna; Palella Jr, Frank J; Chew, Kara W et al. (2018) Prevalence and trends of polypharmacy among HIV-positive and -negative men in the Multicenter AIDS Cohort Study from 2004 to 2016. PLoS One 13:e0203890
Barnert, Elizabeth S; Abrams, Laura S; Tesema, Lello et al. (2018) Child incarceration and long-term adult health outcomes: a longitudinal study. Int J Prison Health 14:26-33
Lidofsky, Anna; Holmes, Jacinta A; Feeney, Eoin R et al. (2018) Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. J Infect Dis 218:1394-1403
Tatsumoto, Narihito; Arditi, Moshe; Yamashita, Michifumi (2018) Sendai Virus Propagation Using Chicken Eggs. Bio Protoc 8:
Chen, Pao-Yang; Chu, Alison; Liao, Wen-Wei et al. (2018) Prenatal Growth Patterns and Birthweight Are Associated With Differential DNA Methylation and Gene Expression of Cardiometabolic Risk Genes in Human Placentas: A Discovery-Based Approach. Reprod Sci 25:523-539
Kim, Jocelyn T; Chang, Emery; Sigal, Alex et al. (2018) Dendritic cells efficiently transmit HIV to T Cells in a tenofovir and raltegravir insensitive manner. PLoS One 13:e0189945
Shen, John; Chang, Jason; Mendenhall, Melody et al. (2018) Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management. Ther Adv Med Oncol 10:1758834017751634

Showing the most recent 10 out of 36 publications